pre-IPO PHARMA

COMPANY OVERVIEW

Arch Oncology is a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of best-in-class antibody therapies for the treatment of patients with cancer. Our next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class.


LOCATION

  • Brisbane, CA, USA
  • St. Louis, MO, USA

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    https://www.archoncology.com


    CAREER WEBSITE

    https://www.archoncology.com/join-us/


    SOCIAL MEDIA


    INVESTORS

    3x5-partners lightchain rivervest-venture-partners roche-venture-fund


    PRESS RELEASES


    Nov 9, 2020

    Arch Oncology to Present New Preclinical Data on Highly Differentiated Anti-CD47 Antibody AO-176 at SITC 2020


    Oct 26, 2020

    Arch Oncology to Present at Upcoming Conferences


    Oct 5, 2020

    Arch Oncology Advances Anti-CD47 Antibody AO-176 into Chemotherapy Combination Phase 1/2 Trial in Solid Tumors


    Jun 22, 2020

    Arch Oncology Announces Formation of Scientific Advisory Board


    Apr 21, 2020

    Arch Oncology Appoints Biotechnology Industry Veteran Julie Hambleton, M.D. to Board of Directors


    For More Press Releases


    Google Analytics Alternative